uniQure (NASDAQ:QURE) Trading Down 6.5% Following Insider Selling

uniQure N.V. (NASDAQ:QURE) dropped 6.5% during trading on Friday following insider selling activity. The company traded as low as $13.99 and last traded at $14.11. Approximately 1,117,485 shares were traded during mid-day trading, a decline of 42% from the average daily volume of 1,932,323 shares. The stock had previously closed at $15.10.

Specifically, insider Jeannette Potts sold 4,670 shares of the firm’s stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $15.14, for a total transaction of $70,703.80. Following the completion of the transaction, the insider now owns 115,073 shares in the company, valued at $1,742,205.22. This trade represents a 3.90% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Analyst Ratings Changes

QURE has been the subject of several analyst reports. HC Wainwright restated a “buy” rating and set a $70.00 target price on shares of uniQure in a research report on Thursday, May 29th. Wells Fargo & Company cut their price objective on uniQure from $35.00 to $30.00 and set an “equal weight” rating for the company in a research report on Friday, February 28th. Wall Street Zen downgraded uniQure from a “hold” rating to a “sell” rating in a research report on Saturday, June 14th. Chardan Capital reiterated a “buy” rating and issued a $38.00 price objective on shares of uniQure in a research report on Friday, May 30th. Finally, Cantor Fitzgerald upgraded uniQure to a “strong-buy” rating in a research report on Monday, May 19th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, six have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $37.82.

uniQure Price Performance

The company has a 50 day moving average price of $14.20 and a 200 day moving average price of $13.89. The company has a market capitalization of $778.42 million, a price-to-earnings ratio of -3.24 and a beta of 0.08. The company has a current ratio of 11.99, a quick ratio of 11.99 and a debt-to-equity ratio of 1.53.

uniQure (NASDAQ:QURE) last released its earnings results on Friday, May 9th. The biotechnology company reported ($0.82) EPS for the quarter, beating the consensus estimate of ($1.07) by $0.25. The company had revenue of $1.57 million during the quarter, compared to analysts’ expectations of $5.93 million. uniQure had a negative return on equity of 483.87% and a negative net margin of 1,077.05%. As a group, equities research analysts forecast that uniQure N.V. will post -3.75 earnings per share for the current year.

Institutional Investors Weigh In On uniQure

A number of institutional investors have recently made changes to their positions in QURE. Avoro Capital Advisors LLC acquired a new stake in shares of uniQure during the fourth quarter worth $38,410,000. Vestal Point Capital LP grew its stake in shares of uniQure by 58.4% during the first quarter. Vestal Point Capital LP now owns 4,792,572 shares of the biotechnology company’s stock worth $50,801,000 after purchasing an additional 1,767,572 shares during the period. RTW Investments LP grew its stake in shares of uniQure by 8,936.3% during the fourth quarter. RTW Investments LP now owns 903,625 shares of the biotechnology company’s stock worth $15,958,000 after purchasing an additional 893,625 shares during the period. Point72 Asset Management L.P. grew its stake in shares of uniQure by 81.3% during the fourth quarter. Point72 Asset Management L.P. now owns 1,771,352 shares of the biotechnology company’s stock worth $31,282,000 after purchasing an additional 794,459 shares during the period. Finally, Boxer Capital Management LLC acquired a new stake in shares of uniQure during the fourth quarter worth $13,245,000. 78.83% of the stock is owned by institutional investors and hedge funds.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.